James Kirwin

SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer.

New Millennium Gaming LLC engages the development of gaming table for live dealer card games that has an electronically controlled felt covered video layout. It introduces Omni-Table, a gaming table which allows for the casino to change the game layout or configuration and add customization to any game. The company was founded on October 10, 2013 and is headquartered in Kingston, PA.

SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer.

SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer.